GlassScriptPhysician profile
Kyle M Rose
NPI 1518311216
$8,973.25
in general payments reported to CMS, 2019-2025
15 companies · $3,100 in 2025
The $3,100 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,271 · 2022: $2,902 · 2023: $131 · 2024: $568 · 2025: $3,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,340 · Food and Beverage: $1,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,340.00 |
| Food and Beverage | $1,459.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $3,060.33 | 2022-2025 | Jelmyto |
| Janssen Global Services, LLC | $2,398.64 | 2025 | |
| Lumenis, INC | $2,000.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $752.54 | 2023-2025 | Balversa, Erleada, Akeega |
| Kerecis Limited | $171.68 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Bioprotect Medical, INC. | $134.92 | 2025 | Bioprotect Balloon Implant System |
| Boston Scientific Corporation | $125.00 | 2019 | |
| Pfizer INC. | $100.06 | 2019 | |
| Janssen Biotech, INC. | $92.29 | 2024-2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $52.85 | 2024 | |
| Dendreon Pharmaceuticals LLC | $26.28 | 2019 | |
| Neotract INC. | $20.11 | 2019 | |
| Abbvie INC. | $19.90 | 2022 | |
| Merck Sharp & Dohme LLC | $18.65 | 2023 | Dificid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.